Neuronetics (STIM) Competitors

BrainsWay (NASDAQ:BWAY) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

Is BWAY or STIM more profitable?

BrainsWay has a net margin of 3.88% compared to Neuronetics' net margin of -50.09%. BrainsWay's return on equity of 3.52% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrainsWay	3.88%	3.52%	2.26%
Neuronetics	-50.09%	-141.24%	-32.77%

Does the MarketBeat Community favor BWAY or STIM?

Neuronetics received 59 more outperform votes than BrainsWay when rated by MarketBeat users. Likewise, 68.45% of users gave Neuronetics an outperform vote while only 66.99% of users gave BrainsWay an outperform vote.

Company	Underperform	Outperform
BrainsWay	Outperform Votes 69 66.99%	Underperform Votes 34 33.01%
Neuronetics	Outperform Votes 128 68.45%	Underperform Votes 59 31.55%

Do analysts rate BWAY or STIM?

BrainsWay presently has a consensus target price of $13.17, indicating a potential upside of 35.18%. Neuronetics has a consensus target price of $4.67, indicating a potential upside of 213.20%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than BrainsWay.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrainsWay	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders and institutionals hold more shares of BWAY or STIM?

30.1% of BrainsWay shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 19.0% of BrainsWay shares are held by insiders. Comparatively, 9.8% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, BWAY or STIM?

BrainsWay has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500.

Which has higher earnings and valuation, BWAY or STIM?

BrainsWay has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrainsWay	$38.63M	4.74	-$4.20M	$0.10	97.40
Neuronetics	$72.71M	0.62	-$30.19M	-$1.23	-1.21

Does the media refer more to BWAY or STIM?

In the previous week, BrainsWay had 4 more articles in the media than Neuronetics. MarketBeat recorded 5 mentions for BrainsWay and 1 mentions for Neuronetics. BrainsWay's average media sentiment score of 1.48 beat Neuronetics' score of 0.98 indicating that BrainsWay is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrainsWay	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BrainsWay beats Neuronetics on 11 of the 17 factors compared between the two stocks.